At what age should the mid‑parental (target) height be calculated for a child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Midparental Height Application in Clinical Practice

Midparental (target) height should be calculated and applied starting at age 2 years and used continuously through childhood until final adult height is reached. This timing aligns with when children transition from WHO growth charts (used for ages <24 months) to CDC growth charts (used from 24 months through 19 years), making it the most practical and evidence-based age to begin systematic comparison of a child's growth trajectory against their genetic potential 1.

Rationale for Age 2 Years as the Starting Point

The age of 2 years represents a critical transition point in growth assessment:

  • Growth chart transition: At 24 months, clinicians switch from WHO growth standards (which reflect optimal growth patterns for breastfed infants) to CDC growth charts that extend through age 20 years 1
  • Measurement methodology change: Length measurements (recumbent) transition to standing height (stature) measurements at this age, creating a natural inflection point for comprehensive growth evaluation 1
  • Growth pattern stabilization: By age 2, children have typically completed their initial deceleration toward their genetic target height, making parental height comparisons more meaningful 2

Application Throughout Childhood (Ages 2-9 Years)

The midparental height calculation becomes most clinically useful between ages 2-9 years, when evaluating whether a child's growth trajectory is appropriate for their familial genetic potential 3, 4:

  • Midparental height accounts for approximately 16% of between-child variability in attained length during this period 5
  • At prepuberty, about 20% of height variation is explained by parental heights, increasing to 30-46% for final adult height 4
  • The correlation between child height and midparental height is approximately 0.4 during this age range 6

Practical Clinical Application

Calculate midparental target height using this formula:

  • For boys: [(Mother's height + Father's height) / 2] + 6.5 cm
  • For girls: [(Mother's height + Father's height) / 2] - 6.5 cm
  • Target range: ±8.5 cm (approximately ±2 standard deviations)

Key clinical scenarios where midparental height is essential:

  1. Distinguishing familial short stature from pathologic growth failure: A child plotting below the 3rd percentile on standard growth charts may be at the 20th percentile when adjusted for small parental heights 3

  2. Identifying non-familial short stature: Children whose height falls below the familially-adjusted 0.4th centile (accounting for parental height correlation of 0.4) warrant further evaluation 6

  3. Avoiding overtreatment: A child with tall parents (97th percentile) plotting at the 25th percentile on standard charts would be at the 3rd centile when parental height is considered, potentially indicating pathology 3

Important Clinical Caveats

Accuracy limitations to consider:

  • Midparental height calculations explain only 11-21% of variability in child length across different populations 5
  • The formula may underestimate adult height in children of very short parents, potentially leading to underestimation of growth potential 7
  • At birth, infants are typically 1.5 z-scores longer than their target height z-score, with deceleration toward target height occurring primarily in the first 2 years 2

Enhanced precision strategies:

  • Including the child's own height at age 1 year increases the proportion of variance explained to approximately 50% 4
  • Using both parents' heights together (midparental height) consistently accounts for more variability than either parent's height alone 5
  • Consider sibling heights for additional familial context in children aged 2-9 years 6

Continuous Monitoring Beyond Age 9

While midparental height is calculated early, continue comparing the child's growth trajectory against their target height throughout puberty and until final adult height is achieved. The predictive value actually increases with age, with parental heights explaining 30-46% of final adult height variation 4. This ongoing comparison helps identify growth disorders that may emerge during puberty and guides decisions about growth-promoting interventions.

References

4
Research

Growth evaluation: parent and child specific height standards.

Archives of disease in childhood, 1989

6
Research

A simple chart to identify non-familial short stature.

Archives of disease in childhood, 2000

Related Questions

Is my 6‑year‑4‑month‑old daughter, who is 131.5 cm tall and growing about 7 cm per year, reaching roughly 73 % of her predicted adult height of 180 cm ± 8 cm, showing normal growth or does she require further evaluation?
What is the predicted adult stature of a son whose father is 6 ft 3 in and mother is 6 ft 0 in?
What is the normal height range for a 12-year-old boy, and when should further evaluation be considered?
If both parents are naturally short, is their 5-year-old child necessarily stunted?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
If both parents are naturally short, is their 5-year-old child necessarily stunted?
Can I use ICD‑10‑CM code T74.11XD for a confirmed adult physical‑abuse case in an outpatient psychiatric follow‑up visit?
For a patient I am now seeing as an inpatient who was previously admitted elsewhere, which ICD‑10‑CM code should I use for confirmed adult physical abuse?
Why would a general practitioner (GP) not refer a patient with a past history of nephrotic syndrome for biliary colic?
In a 79-year-old woman with neurofibromatosis type 1, hyperlipidemia, low bone density, chronic low body weight, insomnia, progressive isolated systolic hypertension, chronic hypotonic hyponatraemia that began after starting valsartan (angiotensin‑receptor blocker), and intermittent mild hyperkalaemia, what is the most appropriate initial management plan?
How is an intra‑articular corticosteroid injection of the right glenohumeral joint performed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.